Abstract: Methods and compositions to extract radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions by utilizing extractant functionalized carbon nanotubes are disclosed. More particularly, phosphorous-containing (such as phosphine oxides, phosphoric acids or phosphates) organic extractants and other predesigned extractants (such as crown ethers, calncrown derivatives, malonamide and diglycolamide derivatives, polyethylene glycol derivatives, cobalt dicarbollite derivatives, and N-donating heterocyclic ligands) can be covalently and/or non-covalently employed on the surfaces and/or ends (tips) of carbon nanotubes for the purpose of removal radionuclides such as various actinides and lanthanides from organic and/or aqueous solutions. Extractant functionalized carbon nanotubes can be used for extracting radioactive nuclides from nuclear waste or spent nuclear fuel, which are produced and/or reprocessed from the nuclear power generation or other nuclear application.

Abstract: Provided are novel crystalline and amorphous forms of ibandronic acid, methods for their preparation, and pharmaceutical compositions containing them. Also provided are methods for purifying and assaying ibandronic acid in any crystalline form (or amorphous).

Abstract: The invention provides certain novel water-soluble and water-insoluble monomers for ring opening metathesis polymerization and novel polymers, compositions and products, and related methods thereof.

Abstract: The present application describes deuterium-enriched ibandronate, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

Abstract: The present invention relates to intermediates of rosuvastatin and processes for the production thereof.

Abstract: The invention relates to a process for the treatment of an aqueous mixture comprising a dipolar aprotic compound, comprising: a) an adsorption step, in which the aqueous mixture is brought into contact with a porous adsorbent, whereby the porous adsorbent is chosen such that the dipolar aprotic compound adsorbs to it more readily than water; b) a desorption step, in which the porous adsorbent is brought into contact with a desorbing agent, whereby a recovery solution is formed comprising the desorbing agent and the dipolar aprotic compound.

Abstract: Provided are novel crystalline forms of ibandronic acid, physical data, methods for their preparation, and uses therefor. Also provided are methods for purifying and assaying ibandronic acid in any crystalline form.

Abstract: The present invention is directed to a compound of formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof, and methods for treating inflammatory and serine protease mediated disorders.

Abstract: A pharmaceutical preparation is disclosed for the prevention, treatment and relief from the consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, Alzheimer's disease, Parkinson's disease, toxic kidney diseases, acute kidney failure, toxic side effects on dosage of chemotherapeutics, diabetes mellitus, Wilson's disease, sideroses and/or ischaemic reperfusion damage, arteriosclerosis and as an antidote against environmental toxins and medicament intoxication. The preparation comprises at least one compound of general formula R-A-X, as active ingredient, where R=straight or branched chain C5-C27 alkyl with double and/or triple bonds and which can be substituted, A=—CO—, —COO—, —POx2?—, —NHy—, —O— and/or —S—, x=2, 3 or 4, y=1 or 2 and X?H, polyol, amino acid, alkylamino, C1- to C3-alkylamino, C1- to C3 hydroxyalkyl and/or 1- to C3-carboxylic acid.

Abstract: Organic compounds are described, which are capable of forming quaternary salts, quaternary salts thereof with a structure having general formula (I) and their use for the control of phytopathogen fungi.

Abstract: The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.

Abstract: The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.

Abstract: Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.

Abstract: Disclosed are ceramide derivatives represented by the following formula 1 or 2, a method for preparing the same, and a therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients: wherein, R1 and R2 are each independently straight or branched alkyl groups having 4 to 22 carbon atoms. The therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients according to the present invention may be useful to treat atopic dermatitis, or treat other skin diseases that are required for improving skin inflammations or suppressing epidermal proliferation, by suppressing or improving inflammatory conditions in the atopic dermatitis in addition to giving immunoregulatory functions, and suppressing or improving skin disorders, for example epidermal proliferation that is generally observed in the atopic dermatitis.

Abstract: The invention concerns a method for the isolation of a stereoisomer from a mixture comprising the two stereoisomers of the general formulae (I-A) and (I-A?) and/or the two stereoisomers of the general formulae (I-B) and (I-B?) in which R1, R2 and R3, identical or different, are selected from the group consisting of —H, —F, —Cl, —C1-C6-alkyl, —S—C1-C6-alkyl, —OH, —O—C1-C6-alkyl, —O—C1-C6-alkylenephenyl, —OCO—C1-C6-alkyl, —OCON(C1-C6-alkyl)2 and —O—SiR8R9R10 (in which R8, R9 and R10, identical or different, are —C1-C6-alkyl or -phenyl); R4 is —H or —C1-C6-alkyl; R5 is —C1-C6-alkyl; and R6 and R7, identical or different, are —H or —C1-C6-alkyl; or their salts with organic or inorganic acids; comprising the step (a) manipulating the mixture ratio of the stereoisomers in the mixture so that at least one of the stereoisomers is present in an enantiomeric excess.

Abstract: The disclosure provides, inter alia, novel bisphosphonate compounds and methods of making and using such compounds. In certain embodiments, compounds of the invention include bisphosphonates that are capable of selectively inhibiting one or more of farnesyl diphosphate synthase (FPPS), geranylgeranyl diphosphate synthase (GGPPS), and decaprenyl pyrophosphate synthase (DPPS). In preferred embodiments, compounds of the invention are capable of selectively inhibiting two or more of FPPS, GGPPS, and DPPS. In embodiments, compounds and methods of the invention demonstrate superior activity levels, such as in the anti-cancer context, immunostimulation context, and other contexts, which in several cases exceed the activity levels of previous generation bisphosphonate drugs by orders of magnitude. In embodiments, the invention provides compounds and methods in connection with research and therapeutic applications, e.g.

Abstract: The invention relates to a novel multi step synthesis of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid, monosodium salt, monohydrate, of the formula

Abstract: The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P1 receptor type. The compounds invention include compounds having a phosphate moiety as well as compounds with hydrolysis-resistant phosphate surrogates such as phosphonates, alpha-substituted phosphonates, and phosphothionates.

Abstract: A material contains at least a polymerizable N,O-functionalized acrylic acid hydroxyamide of the Formula (I) in which A is an n+m-valent linear or branched aliphatic C1 to C50 radical, in which the carbon chain can be interrupted by O, S, —CO—O—, CO—NH, O—CO—NH or NH—CO—NH, an n+m-valent aromatic C6 to C18 radical or an n+m-valent cycloaliphatic or heterocyclic C3 to C18 radical, wherein the radicals can carry one or more substituents, Y is not present, or is O, S, an ester, amide or urethane group, R1 is hydrogen, an aliphatic C1 to C20 alkyl or C3 to C8 cycloalkyl radical which can carry one or more substituents, R2 is H or a C1 to C10 alkyl radical, R3 is not present or is a C1 to C16 alkylene radical which can be interrupted by O, HG is not present, is —COOH, —P?O(OH)2; —P?O(OH)(OR4); —O—P?O(OH)2, —SO2OH or —O—P?O(OH)(OR4), R4 is a C1 to C15 alkyl radical, phenyl or benzyl radical and n is a number from 1 to 5 and m a number from 0 to 3.

Abstract: Disclosed is the use of compounds of formula (I) wherein X, Y and Z are as defined in the description of the invention, for the preparation of an antitumor medicament, optionally in combination with different biologically active substances.

Abstract: The present invention provides an ionic liquid including a quaternary phosphonium salt represented by general formula (1): wherein R1, R2, R3, and R4 each represent a linear alkyl group having 1 to 6 carbon atoms, a branched alkyl group having 3 to 6 carbon atoms, an alicyclic alkyl group having 3 to 6 carbon atoms, or an alkoxyalkyl group represented by —(CH2)nO—R5 (wherein n is an integer of 1 to 6; and R5 represents a methyl group or an ethyl group); at least one of R1, R2, R3, and R4 is an alkoxyalkyl group; R1, R2, R3, and R4 may be the same or different; R1 and R2 together may form a ring; and X represents an anion. The present invention also provides a reaction solvent including the ionic liquid.

Abstract: The present invention relates to a process for the preparation of the alkoxyamine 2-methyl-2-[N-(diethoxy-phosphoryl-2,2-dimethylpropyl)aminoxy]propionic acid or of its salts comprising a stage of saponification of an azo compound in the presence of a base, a stage of photolysis of the salt resulting from the saponification stage in the presence of N-(tert-butyl)-1-diethylphosphono-2,2-dimethylpropyl nitroxide and optionally a stage of acidification of the salt of the alkoxyamine obtained on conclusion of the photolysis stage. The alkoxyamine or its salts can be used as radical polymerization initiators.

Abstract: The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

Abstract: The present invention relates to a process for the manufacture of targeting liposomes comprising vector compounds conjugated to the hydrophilic part of modified phospholipids. The present invention provides the modified phospholipids and liposomes containing said modified phospholipids.

Abstract: The present invention provides bifunctional polymers, methods of preparing the same, and intermediates thereto. These compounds are useful in a variety of applications including the PEGylation of biologically active molecules. The invention also provides methods of using said compounds and compositions thereof.

Abstract: A novel class of compounds that includes HPTS-Cys-MA, and methods of making them are disclosed herein. The class of compounds including HPTS-Cys-MA are useful as fluorescent dyes for analyte detection.

Abstract: The present invention relates to compounds of formula I which are prodrugs of caspase inhibitors and pharmaceutically acceptable salts thereof. This invention further relates to the release of caspase inhibitors from these compounds through selective bond cleavage. This invention further relates to pharmaceutical compositions comprising these compounds, which are particularly well-suited for treatment of caspase-mediated diseases, including inflammatory and degenerative diseases. This invention further relates to methods for preparing compounds of this invention.

Abstract: The preset invention relates to a cost effective, high yielding, reproducible method for the manufacture of alendronic acid or its salt, such as sodium alendronate, from inexpensive and readily available pyrrolidone using phosphonating agents such as PCl3 in the presence of acids such as sulphonic acids, sulphuric acid or phosphoric acid, and pharmaceutical dosage forms of alendronic acid or pharmaceutically acceptable salts thereof.

Abstract: The invention relates to a stable water soluble composition containing lithophosphatidylethanol amine (LPE) or lecithin including the LPE 3% or more. The composition comprises one or both of lysophosphatidylethanol amine and lecithin 0.1 to 50 wt %, fatty acid or salt thereof 0.1 to 60 wt % and solvent 10 to 99.8 wt %. According to the invention, it is possible to provide the stable water soluble composition of lithophosphatidylethanolamine and lecithin which does not cause the precipitation at the room temperature below 20° C. and can maintain the clear formulation even during the long term keeping.

Abstract: The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.

Abstract: Disclosed are ceramide derivatives represented by the following formula 1 or 2, a method for preparing the same, and a therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients: wherein, R1 and R2 are each independently straight or branched alkyl groups having 4 to 22 carbon atoms. The therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients according to the present invention may be useful to treat atopic dermatitis, or treat other skin diseases that are required for improving skin inflammations or suppressing epidermal proliferation, by suppressing or improving inflammatory conditions in the atopic dermatitis in addition to giving immunoregulatory functions, and suppressing or improving skin disorders, for example epidermal proliferation that is generally observed in the atopic dermatitis.

Abstract: A novel form of Ibandronate sodium which is particularly suitable for pharmaceutical applications, and a process for preparing said novel form.

Abstract: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.

Abstract: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N?,N?-tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.

Abstract: One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.

Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.

Abstract: Compounds of formula (I), wherein A is S or O; x is 0 or 1; a is SR10 or N(R11)(R12); R1 and R2 are C1–C24alkyl, OR10, CF3 or halogen; R3, R4 and R5 are hydrogen, C1–C24alkyl, OR10 or halogen; or two of the radicals R11 R21 R31 R4 and/or R9 together form C1–C2oalkylene uninterrupted or interrupted by O, S or NR13; R6, R11 R8 and R9 are hydrogen, C1–C24alkyl; C2–C24alkyl which is interrupted one or more times by non-consecutive O atoms and unsubstituted or substituted by OH and/or SH, or R6, R7, R8 and Rg are OR10; halogen; or phenyl unsubstituted or substituted one or more times by C-Calkyl; R10, R11 and R12 are e.g. hydrogen; X is e.g.

Abstract: The present invention is directed to phosphine ligands and the use of such ligands in catalytic complexes with transition metals. The catalysts may be used in a variety of reactions and are especially useful for refining halogenoaromatics.

Abstract: This invention relates to processes for making phosphorus compounds R2P—X—PR2, R2P-M, R2P-L and R3P, and the novel cation R2P+(L)-X—P+(L)R2, where R represents an optionally substituted hydrocarbyl group, X represents a bridging group, L represents a leaving group and M represents an alkali metal atom. The invention relates further to a process for making a compound R2P-L from a compound R—H via a new process for making the compound R—Li followed by its reaction with a compound Hal2P-L. The compound R2P—X—PR2 is a ligand suitable for making catalysts for copolymerizing carbon monoxide and a olefinically unsaturated compound.

Abstract: The invention relates to stereoisomerically enriched diamines, to metal complexes comprising these diamines and also to their use in a process for asymmetrically reducing ketones using silanes, in particular polymethylhydrosiloxane, as reducing agents.

Abstract: Provided is a novel method of making bisphosphonic acids, e.g. risedronic acid, including the step of combining a carboxylic acid, phoshorous acid, and a halophosphorous compound in the presence of a diluent that is an aromatic hydrocarbon or a silicone fluid. When the diluent is an aromatic hydrocarbon, a inert support or ortho-phosphoric acid codiluent is advantageously included.

Abstract: The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compounds, and to the use of said compounds in the manufacture of pharmaceutical preparations.

Abstract: The invention provides compounds and methods for using them to inhibit the growth of microorganism that expresses Peptide Deformylase, the compounds having the general formula:

Abstract: New hydrate forms of alendronate sodium, having water content of between about one and about twelve percent, and processes for their manufacture, are disclosed. New crystalline forms of alendronate sodium B, D, E, F, G and H, and processes for manufacturing them, are also disclosed. These new forms of alendronate sodium are suitable for incorporation into pharmaceutical compositions for combating bone resorption in bone diseases.

Abstract: Diphosphine of formula I R1R2P—H2C—Ar—CH2PR1R2??(I) are prepared by a process that comprises a) reacting a dimethyl compound of formula II H3C—Ar—CH3??(II) with a base and an N-substituted aminophosphorous halide to form bis(aminophosphinomethyl) compound of the formula III R3R4P—H2C—Ar—CH2—PR3R4??(III) b) reacting the compound of formula III with HCl to form bis(dichlorophosphinomethyl) compound of formula IV Cl2P—H2C—Ar—CH2—PCl2??(IV) and c) reacting the compound of formula IV with an organometallic reagent to give the product compound of formula I, wherein groups R1 and R2 are each, independently of one another, a substituted or unsubstituted aromatic, heteroaromatic or aliphatic hydrocarbon group and may have a covalent bond connecting them and Ar is a substituted or unsubstituted aromatic or heteroaromatic hydrocarbon group an R3 and R4 are each, independently of one another, an N-substituted alkylamino or arylamino group.

Abstract: Disclosed are novel phosphine-phosphoramidite compounds which may be employed in combination with a catalytically-active metal to effect a wide variety of reactions such as asymmetric hydrogenations, asymmetric reductions, asymmetric hydroborations, asymmetric olefin isomerizations, asymmetric hydrosilations, asymmetric allylations, asymmetric conjugate additions, and asymmetric organometallic additions. Also disclosed are a process for the preparation of the phosphine-phosphoramidite compounds, metal complex compounds comprising at least one of the phosphine-phosphoramidite compounds and a catalytically-active metal and hydrogenation processes utilizing the metal complex compounds.

Abstract: Non-C2-symmetric bisphospholane ligands and methods for their preparation are described. Use of metal/non-C2-symmetric bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.

Abstract: The present invention provides pharmaceutical preparations and the uses thereof for preventing and/or treating seizures and other electroconvulsive disorders by administering a pharmaceutically effective amount of a therapeutic compound having the following formula (I): 1

Abstract: Compounds of formula (I), wherein A is S or O; x is 0 or 1; a is SR10 or N(R11)(R12); R1 and R2 are C1-C24alkyl, OR10, CF3 or halogen; R3, R4 and R5 are hydrogen, C1-C24alkyl, OR10 or halogen; or two of the radicals R11 R21 R31 R4 and/or R9 together form C1-C2oalkylene uninterrupted or interrupted by O, S or NR13; R6, R11 R8 and R9 are hydrogen, C1-C24alkyl; C2-C24alkyl which is interrupted one or more times by non-consecutive O atoms and unsubstituted or substituted by OH and/or SH, or R6, R7, R8 and Rg are OR10; halogen; or phenyl unsubstituted or substituted one or more times by C-Calkyl; R10, R11 and R12 are e.g. hydrogen; X is e.g. (II), and R2; have one of the meanings given for R1 and R2; and R3′, R4′ and Rs′ have one of the meanings given for R3, R4 and R5; are suitable as photoinitiators, especially for irradiation with light of relatively long wavelengths.